Medifast (MED) Q4 2025 earnings review
Shrinking to Survive: Productivity Gains Overshadowed by Coach Exodus
Medifast continues its dramatic contraction as the GLP-1 wave reshapes the weight loss industry. Q4 revenue fell 37% YoY to $75.1M, and the active coach count—the lifeblood of the business model—collapsed 41% to just 16,100. While management highlights a 6.2% increase in revenue per coach (the first positive inflection since 2022) as proof of stabilization, the base is vanishing too fast for efficiency to matter. The bottom line swung to a massive loss ($18.1M), exacerbated by a $12.1M non-cash tax valuation allowance, signaling low confidence in near-term profitability. FY26 guidance projects another ~26% revenue decline, indicating the bottom is not yet in.
🐂 Bull Case
For the first time since 2022, revenue per active earning coach grew YoY (+6.2% to $4,664). This suggests the 'Metabolic Health' pivot is resonating with the remaining, higher-quality core of the sales force, potentially validating the new strategy.
Despite operational losses, Medifast holds $167.3M in cash and investments with zero debt. With ~11M shares outstanding, cash per share is ~$15.20, providing a massive valuation floor and runway to execute the turnaround.
🐻 Bear Case
The active coach count plummeted 41% YoY to 16,100. In a direct selling model, losing 40% of the distribution network in a single year creates a negative flywheel that is mathematically difficult to reverse, regardless of productivity gains.
Fixed costs are crushing margins as revenue scales down. SG&A as a percentage of revenue spiked to 79.8% (up 630 bps YoY), and Gross Margin fell to 69.4%. The company is now structurally unprofitable at this revenue level.
⚖️ Verdict: 🔴
Bearish. The cash balance ($15+/share) prevents a failing grade, but the business fundamentals are eroding rapidly. FY26 guidance ($270-$300M) implies the company will be half the size it was in FY24 ($602M). Until the coach count stabilizes, the turnaround is theoretical.
Key Themes
Coach Network Collapse
Reversing the coach decline is the critical missing piece. Active earning coaches dropped from 27,100 in 24Q4 to 16,100 in 25Q4. While management pivoted to 'Metabolic Health' to stem the tide, the acceleration of coach attrition (from -33% in Q1/Q2 to -41% in Q4) indicates the bleeding has not stopped.
Productivity Green Shoot
Accelerating. The bright spot in the report is the efficiency of the remaining workforce. Revenue per coach grew 6.2% YoY to $4,664. Management attributes this to better alignment and the new 'Metabolic Health' messaging. If the company can stop losing coaches, this metric suggests a viable business model exists at the core.
Tax Valuation Allowance
The company recorded a $12.1M non-cash valuation allowance against deferred tax assets. In plain English, this means management does not expect to generate sufficient taxable income in the near future to utilize these assets. It is a formal admission that profitability is not on the immediate horizon.
Significant Deleveraging
Cost cuts are lagging behind the revenue drop. Gross margins compressed 470 bps YoY to 69.4% due to loss of fixed cost leverage. More concerning is SG&A, which, despite falling $27.6M in absolute terms, rose to nearly 80% of revenue. The company is spending $0.80 to generate $1.00 of sales before even accounting for product costs.
GLP-1 Impact & Pivot
The company continues to cite 'rapid adoption of GLP-1 medications' as the primary headwind for client acquisition. The pivot to 'Metabolic Health' is an attempt to coexist with this trend, but the financials suggest the market sees OPTAVIA as a substitute that is being displaced, rather than a complement.
Other KPIs
Stable. Up slightly from $162.3M in the prior year despite the net loss. This indicates that while the P&L is ugly, the business is not burning cash operationally yet, largely due to stock-based comp and balance sheet timing. This cash pile is the primary thesis for holding the stock.
Reversing. Deteriorated from Net Income of $0.8M in 24Q4. Even excluding the $12.1M tax charge, the company posted an operational loss of ~$6M, confirming the slide into unprofitability.
Accelerating. Up 6.2% YoY. This is the highest Q4 productivity figure in two years, driven by the exit of lower-performing coaches and 'efficient coach network structures.'
Guidance
Decelerating. The midpoint ($72.5M) implies a ~37% YoY decline from 25Q1 ($115.7M) and a sequential drop from 25Q4 ($75.1M). The trend has not stabilized.
Stable Negative. Continues the trend of operational losses established in late 2025. Compares unfavorably to the break-even/slight profit levels seen in early 2024.
Decelerating. The midpoint ($285M) represents a ~26% decline from FY25 ($385.8M) and a massive 53% drop from FY24 ($602.5M). Management expects the business to shrink by another quarter.
Key Questions
Coach Stabilization Timeline
With active coaches down 41% YoY, at what specific count do you model the network stabilizing? Is 10,000-12,000 the new normal?
Cost Structure Realignment
SG&A is nearly 80% of revenue. What specific fixed costs can be cut to align with a ~$285M revenue business, or is structurally high SG&A unavoidable due to the coaching model?
Cash Usage Strategy
With $167M in cash and the stock trading near cash value, why is there no mention of buybacks? Are you reserving capital for a potential pivot or acquisition?